Operation manual for control of production, preclinical toxicology and phase I trials of anti-tumour antibodies and drug antibody conjugates. Prepared by a Joint Committee of the: Cancer Research Campaign National Institute for Biological Standards and Control. by unknown
Br. J. Cancer (1986) 54, 557-568
Working Party on Clinical Use of Antibodies
Operation Manual
For
Control of production, preclinical toxicology and phase I trials of anti-tumour
antibodies and drug antibody conjugates
Prepared by a Joint Committee of the:
Cancer Research Campaign
National Institute for Biological Standards and Control
Committee Members: R.H.J. Begent, F. Searle, P.A. Keep, Cancer Research Campaign Laboratories, Department of
Medical Oncology, Charing Cross Hospital, London W6 8RF; R.W. Baldwin, Cancer Research Campaign Laboratories,
University of Nottingham, University Park, Nottingham NG7 2RD; T.A. Connors, Medical Research Council Toxicology
Unit, Medical Research Council Laboratories, Woodmansterne Road, Carlshalton, Surrey SM5 4EF; T.A. Hince,
Scientific Secretary, Cancer Research Campaign, 2 Carlton House Terrace, London SWIY 5AR; J.W.G. Smith, E.
Griffiths, National Institute for Biological Standards and Control, Holly Hill, Hampstead, London NW3 6RB; H.
Waldmann, Clinical School, Medical Research Centre, Addenbrooke's Hospital, Cambridge CB2 2QQ; C. Coombes,
Ludwig Institute, The Haddow Laboratories, Clifton Avenue, Sutton, Surrey SM2 5PX; J.T. Kemshead, Imperial Cancer
Research Fund, Oncology Unit, Institute ofChild Health, 30 Guildford Street, London WC1N IEH, UK.
Scientific correspondence: R.H.J. Begent, Cancer Research Campaign Laboratories, Department of Medical Oncology,
Charing Cross Hospital, London W6 8RF, UK.
Address for reprints: T.A. Hince, Scientific Secretary, Cancer Research Campaign, 2 Carlton House Terrace, London
SWIY 5AR, UK.
© The Macmillan Press Ltd., 1986558 CRC JOINT COMMITTEE
CONTENTS
1 INTRODUCTION
1.1 The situation
1.2 The problem
1.3 The special position of antitumour drugs
1.4 The inadequacy of animal models
1.5 The aim of the minimum toxicological requirement
2 CONTROL REQUIREMENTS FOR ANTIBODIES AND CONJUGATES
2.1 Production and characterisation of the hybridoma cell line and monoclonal antibody
2.1.1 Name
2.1.2 Parent myeloma line
2.1.3 Immune parental cell
2.1.4 Fusion, cloning and recloning
2.1.5 The hybridomna cell line
2.1.6 Activity of the antibody
2.2 Production of the antibody
2.2.1 Seed lot system
2.2.2 In vitro production
2.2.3 In vivo production
2.3 Purification of the antibody
2.3.1 The procedures used
2.3.2 Contaminants
2.4 Stability
2.5 The final product
2.5.1 Appearance
2.5.2 Purity
2.5.3 Pyrogens
2.5.4 Culture
2.5.5 Viruses
2.5.6 A standard
2.5.7 Incompatibilities
2.5.8 Analysis in body fluids or tissues
2.6 Modified antibodies
3 MINIMUM TOXICOLOGICAL DATA
3.1.1 Rationale for trial
3.1.2 Rationale for imaging studies
3.2 Toxicity in mice
3.2.1 Unconjugated antibody
3.2.2 Conjugated antibody
3.2.3 Radiolabelled antibody for diagnostic use
3.2.4 Haematology
3.2.5 HistologyCLINICAL USE OF ANTIBODIES - OPERATION MANUAL 559
4 CLINICAL ELIGIBILITY OF PATIENTS
4.1 Physician responsible
4.2 Original diagnosis
4.3 Disease status
4.4 Predicted survival
4.5 Treatment status
4.6 Haematological requirements
4.7 Biochemical status
4.8 Consent
4.9 Contraindication
5 NUMBER OF PATIENTS TO BE INCLUDED
6 SERIAL OBSERVATIONS
7 DRUG ADMINISTRATION
7.1 Formulation
7.2 Drug administration
7.3 Initial drug schedule
7.4 Initial drug dose
7.5 Escalation protocol in subsequent patients
7.6 Timing of admission of subsequent different patients to treatment
7.7 Dose modification
7.8 Duration of drug administration
7.9 Duration of study
7.10Additional dose schedules
7.11 Recording of toxicity and response
8 SUPPORTIVE THERAPY
8.1 Radiotherapy
8.2 Additional chemotherapy
8.3 Antidotes
9 FLOW OF INFORMATION AND RECORDS
9.1 Study co-ordinator
9.2 Registration
9.3 Toxicity grading
9.4 Tumour response
9.5 Flow sheets
9.6 Summary sheet
9.7 Sudden toxicity procedure
9.8 Data availability
9.9 Regulatory requirements
Appendix 1 Tests on cell seed suspension
Appendix 2 Useful definitions and conversions
Appendix 3 Clinical,haematological andbiochemical data and toxicity related to antibody or conjugated
substance
Appendix 4 WHO performance scale
Appendix 5 Modified Fibonacci escalation
Appendix 6 Definitions oftoxicity
Appendix 7 Tumour response560 CRC JOINT COMMITTEE
1. Introduction
1.1 The situation
Antibodies directed against tumour-associated
antigens have been shown to localise specifically in
tumours in animal models and in patients with a
variety of malignancies including the common
epithelial cancers. They have theoretical potential in
the therapy of cancer when given alone or when
conjugated to an anti-cancer drug. Anti-tumour
activity has been shown in several animal tumour
models and in a few small clinical investigations. It
is important to investigate the efficacy, safety and
quality of this new type of treatment so that any
advantages may be offered to patients with cancer
without undue delay.
1.2 The problem
There is inadequate information on the toxicity to
be expected from administration of antibodies and
drug-antibody conjugates. It is predictable that
existing procedures for phase I and II trials will
cover some of the problems but that new
procedures need to be defined for others. These
include procedures to exclude viruses and poly-
nucleotides from preparations and means of
avoiding tissue damage caused by the localisation
of antibodies in normal tissues.
Guidelines for phase I and II clinical trials of
cytotoxic drugs in the treatment of cancer have
been agreed by the Cancer Research Campaign
Clinical Trials Committee. These have been used as
a basis for the proposed procedures for clinical
trials with antibodies and drug antibody conjugates
with modifications and additions as considered
appropriate.
It is recognised that the requirements of the
licensing authority in regard to physicians under-
taking a limited trial of a drug in their own patients
are less demanding than those required of a drug
company seeking a clinical trial certificate. The cost
of toxicology, which must be borne by grants from
government or charitable sources, would be pro-
hibitive and destructive to the venture if the safety
requirements of the licensing authority were set too
high.
The aim of this document is to establish guide-
lines for the quality and safety of antibodies and
drug antibody conjugates produced in hospitals and
university departments and to establish principles
on which phase I trials of these agents will be
conducted.
1.3 The specialposition ofantitumour drugs
It has become evident that human cancer is, from
the point of view of systemic therapy, a uniquely
human disease. Although similar cancers can be
induced and studied in many animal species, only
generalisations about the disease and its course are
obtained. To acquire more effective antitumour
drugs in humans it has become necessary to exploit
the close interplay of the human response to a
foreign chemical and the vulnerability of the human
tumour.
1.4 The inadequacy ofanimal models
The lack of reliably predictive animal models of
human cancer implies that a drug's therapeutic
potential can only be assessed following careful
studies in man. Accordingly there is a strong
argument, in the case of potential anticancer drugs,
to adopt the minimum animal toxicology require-
ments which are consistent with safety, so that
promising candidates may proceed rapidly to the
clinic. The only valid information obtainable from
animals is an indication of anti-tumour activity, an
indication of antibody localisation in xenografts of
human tumours and an indication of maximum
drug levels with which to commence human toxicity
and anti-tumour trials.
1.5 The aim ofthe minimum toxicological
requirement
The present document summarises recommendations
on the minimum data necessary to satisfy and to
assist the clinician contemplating phase I testing
with all the information he needs whilst at the same
time recognising the cost andfeasibility of obtaining
this information in the laboratory. In addition, the
recommended procedure for the conduct of the
phase I trial itselfis presented.
2. Control recommendations for the antibodies
prepared by academic units for investigational
administration to cancer patients
(Modified from the NIBSC guidelines: 'Considera-
tions for the Standardisation and Control of the
New Generation of Biological Products'.)
An investigator planning to administer monoclonal
antibodies to patients should have considered the
following points and have the appropriate
information available.
2.1 Production and characterisation ofthe
hydridoma cell line and monoclonal antibody
2.1.1 The name of the antibody or conjugate.
2.1.2 The source, name and characterisation of the
parent myeloma line. Details of any synthesis and/or
secretion of immunoglobulin chains by this line
should be documented.CLINICAL USE OF ANTIBODIES - OPERATION MANUAL
2.1.3 The source of the immune parental cell -
species and strain of the spleen cell donor, immuni-
sation procedure and source of immunogen.
2.1.4 A complete description of the fusion, cloning
and recloning procedure.
2.1.5 The characteristics of the hybridoma cell line
with particular reference to the class and, where
appropriate subclass of immunoglobulin secreted: it
should be recorded whether the hybridoma secretes
parent myeloma immunoglobulin chain(s).
Sufficient data should have been obtained to allow
an assessment of the efficiency of the cloning
procedure. The cell line should be stable in respect
of antibody secretion up to and beyond the passage
level used for 'routine' production and precautions
should be taken to avoid contamination with other
cells whether hybridoma or otherwise.
2.1.6 The immunological activity of the antibody
should be characterised: evidence of antigen
specificity and details of immunological reactions
with tissues distinct from the intended target should
be sought.
2.2 Production ofthe antibody
2.2.1 A properly operated seed lot system should
be used for the hybridoma cell line. Wherever
possible tests should be performed on the cell seed
suspension to detect the presence of microbial
contaminant (see Appendix 1).
2.2.2 In vitro production: a description of the cell
culture technique employed. Animal additives
should preferably have been monitored for
potentially pathogenic organisms. The amount and
approximate specific activity of monoclonal anti-
body in the culture supernatant should be routinely
determined and normal criteria for further
processing established. Where beta-lactam anti-
biotics have been used the product may not be
suitable for use in pencillin hypersensitive patients.
2.2.3 In vivo production: the animals used should
be specified, together with the genotype, age,
breeding conditions and apparent health. They
should be inbred, preferably from a pathogen-free
colony which is routinely monitored for potentially
pathogenic organisms. The amount and approxi-
mate specific activity of monoclonal antibody in the
ascitic fluid should be routinely determined and
normal criteria for further processing established.
2.3 Purification ofthe antibody
2.3.1 Details of the procedures used to purify the
antibody from culture supernatant fluid, ascitic
fluid or antiserum should be documented. Where
possible these should be performed with sterile
equipment and reagents.
2.3.2. Contaminants: the capacity of the
purification procedure to remove DNA and RNA
should be known. Procedures which are used to
destroy or inactivate certain contaminants, such as
treatment with deoxyribonucleases, should be
efficacious and innocuous.
2.4 Stability
Data concerning the binding activity of the
antibody and storage conditions (temperature,
duration, proteolytic enzyme inhibitors added)
should be documented.
2.5 Thefinalproduct
2.5.1 The appearance, colour, form in which
presented should be given.
2.5.2 Precise criteria for the purity of the
immunoglobulin product should be established.
These should include tests with limits for
homogeneity (e.g., by a variety of electrophoretic
procedures); specification with limits, for specific
activity (antibody activity per unit weight protein)
and the presence of aggregates.
2.5.3 The final product should be pyrogen-free.
2.5.4 The final product should be negative on
culture for bacteria and mycoplasma and should be
filtered before administration.
2.5.5 The antibody should be treated to inactivate
viruses either in the final product form or at an
earlier stage; the method used should be specified
and shown to be efficacious and innocuous (e.g.,
gamma irradiation or heat treatment).
2.5.6 Material from an early batch should be
retained as a standard for comparing future
batches.
2.5.7 Injected materials should be free of gross
aggregates and particles: high speed centrifugation
and/or filtration through an appropriate membrane
may be necessary.
2.5.8 Details of proposed methods for qualitative
or quantitative analysis in body fluids or tissues
should be established.
2.6 Modified antibodies
For some purposes it may be desirable to modify
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monoclonal antibodies, e.g., by conjugation with a
toxin, radiolabelling, attachment to specific drugs
or proteolytic digestion. For such products
additional specific control procedures are necessary.
These include determination of the molecular
weight of the conjugate and evidence of antigen
binding activity and of activity, stability and
pharmacokinetics of the conjugated drug. Any
known incompatibilities with other drugs should be
stated.
3. Minimum toxicological data for products of
hospitals or academic units (for use in a limited
number ofpatients)
3.1.1 Rationalefor therapeutic trial
The rationale for treatment must include:
(a) clear evidence of special or general anti-tumour
activity in experimental systems.
and
(b) evidence of specific in vivo tumour localisation
of the antibody in patients with a defined
histological tumour type which may reasonably
respond to the antibody or drug-antibody
conjugate.
or
(c) a selective effect on a normal self-renewal
system which would reasonably be expected to
provide an agent useful against a human
tumour recognised as a neoplastic trans-
formation of that self-renewal system or part of
it.
3.1.2 Rationalefor imaging studies with
radiolabelled antibody
The rationale for imaging studies should include:
1. evidence of localisation of antibody to the
appropriate type of tumour cell by immuno-
cytochemistry.
and/or
2. evidence of in vivo localisation of antibody in a
xenograft of the appropriate human tumour in
experimental animals.
and/or
3. evidence of in vitro binding of antibody to a
purified tumour associated antigen expressed in
the relevant human tumour type.
3.2 Toxicity studies
Appropriate toxicity, histology and haematology
will be available following either i.p. or i.v. route
depending on the solubility of the agent and the
expected mode of administration in the clinic. It is
envisaged that studies will be conducted in animals
of one sex, usually male.
3.2.1 Unconjugated antibody
If the purity and specificity (with particular
reference to 3.1.lb and c) have been shown to be
satisfactory it is expected that the results of single
dose toxicity studies should be available. These
studies will normally be conducted in mouse (i.e.
the species frequently used in antibody production)
and one other species, e.g. guinea pig or rabbit. The
number of animals required is in the order of 6-10
per dose. The dose given should be 10 times that
proposed in man on a pro rata basis (e.g. mgkg-1).
In certain circumstances a second dose may be
advisable, for example in order to cover the
possible need for dose escalation in man. The aim
of the study is to identify any untoward or un-
expected effect of the antibody. All animals should
be sacrificed 14 days after dosing and subjected to
gross pathological examination. Histopathology
should be carried out on any tissues which are
macroscopically abnormal. Haematology will also
usually be performed (see Sections 3.2.4 and 3.2.5).
3.2.2 Conjugated antibody
(a) Single dose studies (usually in male animals)
i. Antibody linked to a known cytotoxic agent An
estimate of the LDIO of the conjugate should be
obtained in mice and another species, e.g. guinea-
pig or rabbit using 6-10 animals/dose. It is antici-
pated that the approximate lethality of the cyto-
toxic agent alone and the antibody alone will be
available.
Animals from these studies treated with the
LDIO should be observed and weighed for 14 days
and then subjected to full histopathological and
haematological investigation (see Sections 3.2.4 and
3.2.5).
(a) ii. Antibody linked to an unknown cytotoxic
agent An estimate of lethality (e.g. LD1O) of the
cytotoxic agent alone and of the conjugate should
be obtained in mice and another species (e.g. rabbit
or guinea-pig) using 6-10 animals/dose. Those
animals which were treated with the LDIO of the
conjugate should be observed and weighed for 14
days and then be subjected to full histopathological
and haematological examination (see Sections 3.2.4
and 3.2.5).
(b) Multiple dose studies If multiple dose therapy
is planned in patients, the estimated LD1O or 10
times the proposed patient dose should be used, for
example, in a course, of 5 successive daily
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rabbit or guinea-pig). Sufficient animals should be
used to enable some to be sacrificed at the end of
the dosing period and some to be observed and
weighed for a subsequent 28 days prior to sacrifice.
All animals should be subjected to full histopatho-
logical and haematological examination (Sections
3.2.4 and 3.2.5). Should toxicity be evident at this
dosage it will be necessary to repeat the experiment
using a lower dose in order to ascertain a no or
minimal effect level.
3.2.3 Radiolabelled antibodyfor diagnostic use
If the purity and specificity of the antibody have
been shown to be satisfactory it is expected that
very limited toxicity testing would be conducted. It
is suggested that if the radiolabel is replacing a
normal atom or molecule, for example tritium
replacing hydrogen, then there is no need for
studies other than those outlined for the uncoju-
gated antibody (see Section 3.2.1). Where the radio-
label forms an addition product with the antibody
it may be advisable to carry out the studies using a
cold product prepared in the same way as the
radiolabelled product but for example substituting
iodine 127 instead of 131. If this is not possible
then toxicity studies should be done using the
unconjugated antibody only.
3.2.4 Haematology
For toxicity studies, a total red cell, white cell and
platelet count together with differential assessment
of white cell components are to be obtained
together with a bone marrow smear.
3.2.5 Histology
The following tissues will be examined - bone
marrow (squash preparation), kidney, liver, spleen,
heart, lung, gut, brain and testis. Any perturbation
from normally will be described in detail. Histology
of all intercurrent deaths is required.
4. Clinical eligibility of patients
In addition to the information outlined below, the
following publication is recommended for more
detailed considerations:
WHO Handbook for Reporting Results of Cancer
Treatment,
WHO Offset Publication No. 48,
World Health Organisation,
Geneva 1979.
Obtainable from HMSO.
4.1 Physician responsible
Each patient should be in the care of a cancer
physician experienced in management of the relev-
ant tumour type and familiar with investigation of
new drugs and management of drug toxicity.
4.2 Original diagnosis
Microscopically confirmed diagnosis of cancer.
4.3 Disease status
Disease progression despite accepted first line
therapy where this exists.
4.4 Predicted survival
A predicted survival of not less than 4 months.
4.5 Treatment status (for therapeutic studies)
At least a three week interval since the last dose of
other potentially myelosuppresive therapy and
recovery from reversible toxicity.
4.6 Haematological requirements
Minimal haematological requirements: WBC
>3,000mm 3; platelets > 100,000mm 3 (excluding
patients with acute leukaemia).
4.7 Biochemical status
Minimal biochemical parameters: normal values
for organs related to drug metabolism and
excretion or related to major toxic manifestations.
Deviations up to 25% above the upper limit of
normal liver function will be acceptable however.
4.8 Consent
No patient will be entered into the study without
his or her consent or that of a parent or guardian
for those under 16 years, following a full
explanation of the purpose and limited expectations
of the study.
4.9 Contraindication
Pregnancy, acute intercurrent complications.
History of allergy to immunoglobulins of the same
species. Positive immediate type hypersensitivity
reaction on intradermal testing with antibody. Other
concomitant anti-cancer therapy. Performance
status: WHO scale 3-4.
5. Number of patients to be included
If it is intended to escalate the dose,
scheme is recommended:
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Usually two patients per nontoxic dose level but at
least three patients at levels producing limiting
toxicity. Seven to ten patients at drug levels with
acceptable, reversible toxicity.
6. Serial observations
Appendices 3, 4, 6 and 7 summarise minimum
requirements. Additional parameters and/or
increased frequency of determinations might be
required, depending on animal toxicology and on
the needs for the best clinical management of the
patient.
7. Drug administration
7.1 Formulation
See 2.3-2.5.
7.2 Drug administration
Means to treat anaphylaxis should be available.
Route to be stated, e.g. i.v. bolus or infusion over a
defined time period.
7.3 Initial dose schedule
The maximum starting dose will be based on 1/10th
of the LDIO in mouse given i.v. An arbitrary dose
will be needed if the LD1O cannot be attained but
10 times this dose must have been shown to be at
or below the LD10 in mice and in a species other
than that from which the antibody originates if the
antibody is of mouse or rat origin.
7.4 Initial drug dose
Drug doses are given in mgm-2 body surface area.
Two patients will be entered at the starting dose
level (see Appendix 2).
7.5 Escalation protocol in subsequent patients
Subsequent patients will be entered at higher dose
levels, if no dose-limiting toxicity occurs at the
preceding dose level. Normally 3 patients should be
entered at each dose level. Consideration may be
given to escalating the dose in the same patient or
in different patients although these are likely to give
different results if patients become immunised to
antibody after 1 or more doses.
The dose increments will diminish as the level of
expected toxicity is reached and a commonly used
escalation protocol is outlined in Appendix 5.
7.6 Timing ofadmission ofsubsequent different
patients to treatment
A time interval of at least 10 days should pass
between administration of a drug to one patient
and the admission of the next patient at the same
dose level.
At least three weeks should pass before entry of
further patients into the next higher dose level, in
order to take advantage of the experience gained at
lower dose levels. The time intervals may be
increased as levels of expected drug toxicity are
reached.
7.7 Dose modification
Consideration should be given to interrupting
medication when there is evidence of hyper-
sensitivity, a major adverse effect of bone marrow
except in patients with acute leukaemia or whenever
other complications occur.
Medication should also be interrupted or dis-
continued whenever this is regarded to be in the
best interests ofthe patient, irrespective oftoxicity.
7.8 Duration ofdrug administration
This will have to be established as experience is
gained.
7.9 Duration ofstudy
The patients are followed for at least 3 weeks after
the last drug dose; longer if there is toxicity.
7.10 Additional dose schedules
It may be desirable to explore more than one dose
schedule of drug administration (e.g. continuous i.v.
infusion or daily 5 day doses).
The starting level for drug dose is 1-2 dose steps
below the level of expected toxicity and depends on
the experience gained with the initial dose schedule
(type of toxicity, reversibility of toxicity, variability
of individual tolerance).
7.11 Recording oftoxicity and response
Appendices 3 and 4 give guidelines to be used in
addition to history, examination and any other
relevant investigation.
8. Supportive therapy
Full supportive care and treatment will be given to
each patient (antibiotics, transfusions, diet, etc.).
Hospitalisation should be recommended for agents
with unpredictable toxicity.CLINICAL USE OF ANTIBODIES - OPERATION MANUAL 565
8.1 Radiotherapy
May be given as a palliative measure. If major
areas of haematopoietic tissue need to be irradiated,
the patient will be excluded from further study.
8.2 Additional chemotherapy
Administration of other antineoplastic agents
during the study period disqualifies the patient
from the study.
8.3 Antidotes
A record of all concurrent non-antitumour drugs
used should be provided at the end of the study.
9. Flow of information and records
9.1 Study co-ordinator
A co-ordinator will be appointed to collate all
studies on a single drug within a group.
9.2 Registration
Qualifying patients are registered with the study co-
ordinator for assignment of drug dose and starting
date.
9.3 Toxicity grading
See Appendix 6.
Appendix 1
Tests on cell seed suspension
Wherever possible tests should be performed on the
cell seed suspension to detect the presence of
microbial contaminants.
For the isolation of bacteria, fungi and myco-
plasma, samples should be inoculated into culture
media suitable for the growth of these micro-
organisms.
For the detection of viruses, samples of disrupted
cells, suspended in serum free medium, should be
inoculated into 10 suckling mice, of a different
strain to those used to prepare the hybridoma cell
line where this is of mouse origin, and 5 guinea-
pigs. Each mouse should be inoculated i.p. with
0.1 ml of cell suspension. Each guinea-pig should be
inoculated i.p. with 2.0ml. The animals should be
observed for at least 4 weeks for evidence of disease
or failure to thrive. Such animals should be
examined to determine as far as possible the cause
of pathology.
9.4 Tumour response
See Appendix 7.
9.5 Flow sheets
Flow sheets including tumour measurements will be
used to record day to day observations on
symptoms, signs and laboratory data.
9.6 Summary sheet
See Appendix 8.
A summary sheet will be prepared by the study
co-ordinator.
9.7 Sudden toxicity procedure
The study co-ordinator is called at once in case of
pronounced toxicity; he/she will inform the investi-
gators in charge of other patients in the study.
9.8 Data availability
The summary form and flow sheets to be made
available to the Phase I Clinical Trials Committee
at the completion of the study, or at any other time
suggested by the Phase I Clinical Trials Committee.
9.9 Regulatory requirements
A form for doctors and dentists exemption
certificates must be submitted to the DHSS (form
MLA 162).
If possible, tests for viruses should also be
performed by inoculation of cell cultures of human
(e.g. MRC-5 cells) and monkey origin (e.g. VERO
cells). The cultures should be incubated at 35°C
and observed for cytopathogenic changes.
Appendix 2
Useful definitions and conversions
Definitions of toxicity (1) HNTD (highest non-
toxic dose) - the highest dose at which no haemato-
logic, chemical or morphological drug induced
alterations occur.
TDL (toxic dose low =2 x HNTD) - the lowest
dose which produced drug induced pathological
alterations in haematological, chemical, clinical or
morphologic parameters.
TDH (toxic dose high =2 xTDL) - the dose
which produces drug-induced pathologic alterations
in haematologic, chemical, clinical or morphologic
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LD (lethal dose=2 xTDH) - the lowest dose
which produces drug-induced death in any animal
during the treatment or observation period.
In rodents LD10 is considered to be the maximum
tolerated dose (MTD)
of mgkg-1 to mgm-2 for different
fxmgkg- =mgm-2
Species (f)
Mouse 3.0
Rat 6.0
Dog 20.0
Monkey 12.0
Human-based on both weight and
Formula of Dubois and Dubois (3):
s-=WO.425x H0 725 x 71.84
or log S=0.425log W+0.725logH+ 1.8564
S=body surface area in cm2.
W=weight in kg.
H=height in cm.
height.
Appendix 3
Clinical, haematological and biochemical data and
toxicity related to cytotoxic or other drugs.
End of
Parameter Onset Weekly study
Clinical examination
(inc. tumour
meas., no) x x
Body weight x x x
WBC and diff x x x
Hb x x x
Platelets x x x
Bilirubin, Alk, Phos x x x
SGOT (SGPT) x x x
LDH, Prothrom. time x x x
Creatinine x x x
Uric acid x x x
Urine x x x
Chest X-ray x every 2-4 weeks x
WHO Performance
Status at each
visit x where indicated x
Blood urea x x x
Electrolytes x x x
Bone marrow where indicated
The determination of obligatory and non-obligatory
parameters will be made for each agent during the
production ofeach individual protocol.
Translation ofMTD in mice to Phase I starting dose
in humans
It was concluded by Freireich et al. (1) and Owens
(2) that on a mgm-2, the MTD was, on average,
similar in each animal species. It was concluded
that: 1/6 LDIO in mouse could be used provided
this amount is not life threatening or lethal in the
dog.
An alternative in the absence of dog toxicity data
is to use 1/10th LD10 (mouse) that would probably
always be tolerated in the dog. The latter is the
recommended procedure.
References
(1) FREIREICH, E.J., GEHAN, E.A., RALL, D.P., SCHMIDT,
L.H. & SKIPPER, H.E. (1966). Quantitative comparison
of toxicity of anticancer agents in mouse, rat, hamster,
dog, monkey, and man. Cancer Chemotherapy Rep.,
50, 219.
(2) OWENS, A.H.J. (1963). Predicting anticancer drug
effects in man from laboratory animal studies. J.
Chronic. Dis., 15, 223.
(3) DUBOIS & DUBOIS (1916). Arch. Intern. Med., 17, 863.
Toxicity related to antibody
End of
study
Day (see
Onset 1 2 Weekly 7.9)
Total IgG
Total IgM
Total IgA
Total complement
C3
C4
Rheumatoid factor
Circulating
immune
complexes
Human antibody
to administered
antibody
Creatine clearance
24 hour urine
protein
Urine red cells
Urine white cells
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x x x
x
x
x
x
x
x
Ifplasma urea
rises
Ifprotein on
routine testing
x
Conversion
species:
x
x
x
x
x
x
x
x
x
x
xCLINICAL USE OF ANTIBODIES - OPERATION MANUAL 567
Appendix 3-continued
End of
study
Day (see
Onset 1 2 Weekly 7.9)
Urine casts x x
Peak flow x x x x x
ECG x after 7 days x
Chest X-ray x after 7 days x
Clinical history
and examination x x x
Toxicity related to conjugated substance
(131 Iodine in this case)
Serum T4 x Monthly
indefinitely
Serum TSH x Monthly
indefinitely
Appendix 4
WHO Performance Scale
Scale Performance
0 Able to carry out all normal activity without
restriction.
1 Restricted in physically strenuous activity
but ambulatory and able to carry out light
work.
2 Ambulatory ahd capable of all self-care but
unable to carry out any work; up and about
more than 50% ofwaking hours.
3 Capable of only limited self-care; confined to
bed or chair more than 50% of waking
hours.
4 Completely disabled; cannot carry on any
self-care; totally confined to bed or chair.
Appendix 5
Modified Fibonacci escalation
Percentage increase above
Drug dose preceding dose level
na
2n 100
3.3n 67
5n 50
7n 40
9n 30-35
12n 30-35
16n 30-35
aStarting does n (mgm2).
Appendix 6
Definitions oftoxicity
Toxicity: Always related to a given dose schedule
at a given dose level for a given duration
of time.
Grade 0 Nontoxic dose: A dose which causes no
recognisable effects whatsoever.
Grade 1 Subtoxic dose: A dose which causes
consistent changes of haematological or
biochemical or other parameters and
might thus herald toxicity at the next
higher dose level or with prolonged drug
administration.
Grade 2 Minimal toxic dose: The smallest dose at
which one or more patients show consis-
tent, readily reversible drug toxicity.
Grade 3 Recommended dose for therapeutic
trial: The dose which causes moderate
reversible toxicity in the majority of
patients.
Grade 4 Maximally tolerated dose: The highest
tolerable, safe dosage.
Appendix 7
Tumour response
Tumour masses are counted and measured at
regular intervals. Measurable tumour masses are
defined as the product of the longest xthe widest
perpendicular diameter. The third dimension can be
added, where possible. Measurability is arbitrarily
defined as reproducibility of simultaneous
measurements within 50% by independent
observers.
1. Complete tumour regression is defined as
complete disappearance of all recognisable
tumour masses and/or biochemical changes
directly related to the tumour.
2. Complete remission is defined as complete
tumour regression (1) and complete
disappearance of all indirect (host mediated)
symptoms, signs, haematological, and
biochemical parameters.
3. Partial regression is defined as >50% decrease
of one of more tumour lesions in the absence of
progression or occurrence of new lesions
elsewhere.
4. Improvement applies only to well-outlined
palpable lesions, and is defined as >25 to
<50% regression in the absence of progression
or occurrence of new lesions elsewhere.
5. Stable disease: Changes smaller than those
outlined under (3), (4) and (6).568 CRC JOINT COMMITTEE
6. Progressive disease: Occurrence of any new
lesion or increase of well-outlined, palpable
lesions by 33% or increase of any other
measurable lesion by >100% irrespective of
regressions elsewhere.
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